NovoCure (STU:038) FFO


STU:038 NovoCure Ltd STU:038
72 GF Score
Price €13.47
GF Value €16.31
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure FFO?

FFO (Funds from operations) only applies to REITs.

STU:038
72GF Score
NovoCure Ltd STU:038
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NovoCure (STU:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €13.47 is trading 17.4% below its estimated GF Value™ of €16.31. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for STU:038:

  • FFO:
  • GF Value™: €16.31 vs. price of €13.47 (17.4% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
72GF Score

Get the complete analysis for STU:038

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.47
Price
€16.31
GF Value